ClinicalTrials.gg
Drug

Daridorexant clinical trials

Also written ACT-541468.

studies test it
46
open now
12
in phase 3
6
first study started
2015

How each study uses daridorexant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the daridorexant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
7 Jan 2022 · QUVIVIQ · NDA 214985 (FDA, Drugs@FDA)
European Union
29 Apr 2022 · Quviviq · EMEA/H/C/005634 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Daridorexant
16
Daridorexant 50 mg
12
Daridorexant 25 mg
5
Daridorexant 10 mg
3
ACT-541468 25 mg
2

Brand

Quviviq
1

Development codes

ACT-541468
14

Studies by the year they started

45 studies that test it; most in 2018 (7); 1 more planned to start later

Studies that test daridorexant, by start year
YearStudies
20153
20162
20173
20187
20195
20202
20224
20236
20243
20253
20267

By phase

A phase 1/2 study counts in both.

Phase 1
24
Phase 2
8
Phase 3
6
Phase 4
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 34 · Other 12

Idorsia Pharmaceuticals Ltd. (31) · University of Rochester (2) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · Nxera Pharma Korea Co., Ltd. (1) · Wang Fengmei (1) · Xuanwu Hospital, Beijing (1) · Sterling McPherson (1) · Institut d'Investigació Biomèdica de Bellvitge (1)

Often tested with

Tested in the same studies.

Rosuvastatin (1) · Midazolam (1) · Warfarin (1) · Efavirenz (1) · Zopiclone (1) · Citalopram (1) · Trazodone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 1 in phase 3

Studies that test daridorexant, phase 3 first.

Studies

Open first, then newest update. How each study uses daridorexant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 46

See all 46 studies that test daridorexant →

As the comparator · 1 — what is tested is compared with daridorexant

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call daridorexant · ClinicalTrials.gg INT001169

  • MeSH (NLM) C000634383daridorexantConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) LMQ24G57E9DARIDOREXANTConfirmed FDA, NLM, Wikidata
  • RxNorm 2591497One source FDA
  • Wikidata Q55112806daridorexantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174674DaridorexantOne source FDA
  • DrugBank DB15031One source Wikidata

Also registered as daridorexant hydrochloride (UNII 9X9581N56R · RxNorm 2591496).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.